

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50304/128001 10/583,814 Bondy et al. June 4, 2007 1625 June 11, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	US-2,191,978	2/27/1940	Balle and Horst
	US-2,411,662	11/26/1946	Martin and Gysin
	US-2,516,674	7/25/1950	Havertown and Seifter
	US-2,548,863	4/17/1951	Havertown and Seifter
	US-3,985,891	10/12/1976	Kutter et al.
	US-4,358,387	11/9/1982	Zoleski et al.
	US-4,565,816	1/21/1986	Neumann
	US-4,692,443	9/8/1987	Katner
	US-4,804,658	2/14/1989	Manley et al.
	US-4,914,108	4/3/1990	Khanna et al.
	US-4,988,707	1/29/1991	Stealey et al.
	US-5,019,581	5/28/1991	Khanna et al.
	US-5,057,517	10/15/1991	Johnston et al.
	US-5,208,242	5/4/1993	Khanna et al.
	US-5,332,744	7/26/1994	Chakravarty et al.
	US-5,374,638	12/20/1994	Dhanoa et al.
	US-5,405,964	4/11/1995	Mederski et al.
	US-5,438,063	8/1/1995	Osswald et al.
	US-5,587,372	12/24/1996	Aszodi et al.
	US-5,607,944	3/4/1997	Linz et al.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

EXAMINER <u>/Nilooftar Rahmani/</u>	DATE CONSIDERED <u>09/02/2009</u>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50304/128001 10/583,814 Bondy et al. June 4, 2007 1625 June 11, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS			
	US-5,854,265	12/29/1998	Neville J. Anthony
	US-5,859,035	1/12/1999	Anthony et al.
	US-5,872,136	2/16/1999	Anthony et al.
	US-5,874,452	2/23/1999	Neville J. Anthony
	US-5,880,140	3/9/1999	Neville J. Anthony
	US-5,883,105	3/16/1999	Neville J. Anthony
	US-5,939,557	9/17/1999	Anthony et al.
	US-6,051,574	4/18/2000	Neville J. Anthony
	US-6,063,930	5/16/2000	Dinsmore et al.
	US-6,080,870	6/27/2000	Anthony et al.
	US-6,329,381	12/11/2001	Kurimoto et al.
	US-6,376,515	4/23/2002	Zhu et al.
	US-6,479,508	11/12/2002	Beaulieu et al.
	US-6,492,384	12/10/2002	Mederski et al.
	US-2003/0073836	4/17/2003	Priepke et al.
	US-20030108862	6/12/2003	Kukolj et al.
	US-6,627,651	9/30/2003	Shiraishi
	US-20040082635	4/29/2004	Hashimoto et al.
	US-20040097438	5/20/2004	Hashimoto et al.
	US-20040097574	5/20/2004	Marshall
	US-6,767,654	7/27/2004	Tamao et al.
	US-6,770,666	8/3/2004	Hashimoto et al.

EXAMINER	/Niloofar Rahmani/	DATE CONSIDERED	09/02/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

U.S. PATENT DOCUMENTS			
	US-20040171626	9/2/2004	Beaulieu et al.
	US-20040186125	9/23/2004	Poupard et al.
	US-6,803,374	10/12/2004	Priestley et al.
	US-6,835,739	12/28/2004	Zhu et al.
	US-6,844,367	1/18/2005	Zhu et al.
	US-20050026921	2/3/2005	Eckhardt et al.
	US-20050096337	5/5/2005	Ackermann et al.
	11/658,625	7/26/2005	Kim et al.
	US-20050222198	10/6/2005	Bondy et al.
	US-20050239821	10/27/2005	Neyts et al.
	US-20060052602	3/9/2006	Kim et al.
	US-7,026,051	4/11/2006	Schauer et al.
	US-7,098,231	8/29/2006	Poupard et al.
	US-7,112,600	9/26/2006	Hashimoto et al.
	US-20060229336	10/12/2006	Kazmierski et al.
	US-20070021472	1/25/2007	Zhu et al.
	US-20070032497	2/8/2007	Hashimoto et al.
	US-7,223,785	5/29/2007	Beaulieu et al.
	US-7,285,551	10/23/2007	Hashimoto et al.
	US-7,294,457	11/13/2007	Kukolj et al.
	12/303,207	2/12/2008	Steven S. Bondy
	US-20080188516	8/7/2008	BONDY et al.

EXAMINER	/Niloofar Rahmani/	DATE CONSIDERED	09/02/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50304/128001 10/583,814 Bondy et al. June 4, 2007 1625 June 11, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS			
	US-20080199427	8/21/2008	Steven S. Bondy
	US-20090036460	2/5/2009	Dowdy et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Applicant	Translation (Yes/No)
	AU-643289	6/14/1991	Callinan Lawrie	
	CA-2093290	7/10/1993	Merck Patent Gmbh	
	CA-2158996	3/14/1994	Bayer Aktiengesellschaft	
	CA-2357771	7/13/2000	Merck Patent Gmbh	
	CA-2423800	3/25/2003	Japan Tobacco Inc	
	CA-2471566	1/7/2003	Boehringer Ingelheim Pharma	
	CA-2496249	8/19/2003	Boehringer Ingelheim Pharma	
	DE-4211474	10/7/1993	Merck Patent Gmbh	
	DE-4230464	3/17/1994	Merck Patent Gmbh	
	DE-4236026	6/16/1994	Merck Patent Gmbh	
	DE-4309969	9/29/1994	Bayer Ag	
	DE-4318813	12/8/1994	Merck Patent Gmbh	
	EP-0138552	4/24/1985	Lilly Co Eli	
	EP-0228845	7/15/1987	Fujisawa Pharmaceutical Co	
	EP-0232937	8/19/1987	Janssen Pharmaceutica Nv	
	EP-0300726	1/25/1989	Merck & Co Inc	

EXAMINER <i>/Nilofar Rahmani/</i>	DATE CONSIDERED <i>09/02/2009</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50304/128001 10/583,814 Bondy et al. June 4, 2007 1625 June 11, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	EP-0462009	12/18/1991	Roussel Uclaf
	EP-0510260	10/28/1992	Toyo Jozo Kk
	EP-0605836	7/13/1994	Meiji Seika Kaisha
	EP-0706795	4/17/1996	Pfizer
	EP-1162196	12/12/2001	Japan Tobacco Inc
	EP-1386923	2/4/2004	Sumitomo Pharma
	EP-1400241	2/4/2004	Japan Tobacco Inc
	GB-2264115	8/18/1993	British Bio Technology
	HU-78019	5/28/1999	Horvath Andras et al.
	IL-89588	3/13/1989	G.D. Searle & Co.
	SU-1048742	12/23/1986	Inst Fiz Orch Khim Uglekhimii et al.
	SU-813921	12/23/1986	Inst Fiz Orch Khim Uglekhimii et al.
	SU-851940	4/30/1988	Inst Fiz Orch Khim Uglekhimii et al.
	SU-860463	5/27/1998	Inst Fiz Orch Khim I Uglekhimi et al.
	WO-00/20400	4/13/2000	Axys Pharm Inc et al.
	WO-00/20416	4/13/2000	Merck Patent Gmbh et al.
	WO-00/20425	4/13/2000	Rhone Poulenc Chimie et al.
	WO-00/20445	4/13/2000	Chaux Pascal et al.
	WO-00/39127	7/6/2000	Du Pont Pharm Co
	WO-00/40583	7/13/2000	Merck Patent Gmbh et al.
	WO-00/40586	7/13/2000	Chisso Corp et al.
	WO-00/73307	12/7/2000	Univ Virginia et al.

EXAMINER	/Niloofar Rahmani/	DATE CONSIDERED	09/02/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50304/128001 10/583,814 Bondy et al. June 4, 2007 1625 June 11, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	WO-01/60315	8/23/2001	Iaf Biochem Int et al.
	WO-01/66526	9/13/2001	Cermol Sa et al.
	WO-01/85172	11/15/2001	Smithkline Beecham Corp et al.
	WO-01/95910	12/20/2001	Squibb Bristol Myers Co
	WO-02/04425	1/17/2002	Boehringer Ingelheim Ca Ltd et al.
	WO-02/057425	7/25/2002	Merck & Co Inc et al.
	WO-02/067942	9/6/2002	Smithkline Beecham Corp et al.
	WO-03/000254	1/3/2003	Japan Tobacco Inc et al.
	WO-03/004020	1/16/2003	Boehringer Ingelheim Pharma et al.
	WO-03/007945	1/30/2003	Boehringer Ingelheim Ca Ltd et al.
	WO-03/010140	2/6/2003	Boehringer Ingelheim Ca Ltd et al.
	WO-03/010141	2/6/2003	Boehringer Ingelheim Ca Ltd et al.
	WO-03/014229	2/20/2003	Forsch Pigmente Und Lacke E V et al.
	WO-03/026587	4/3/2003	Squibb Bristol Myers Co
	WO-03/057205	7/17/2003	Boehringer Ingelheim Pharma et al.
	WO-04/018468	3/4/2004	Boehringer Ingelheim Pharma et al.
	WO-04/019935	3/11/2004	Boehringer Ingelheim Pharma
	WO-04/033455	4/22/2004	Novo Nordisk As et al.
	WO-04/043913	5/27/2004	Trimeris Inc
	WO-04/054974	7/1/2004	Smithkline Beecham Corp et al.
	WO-04/072243	8/26/2004	Enanta Pharm Inc et al.
	WO-05/063744	7/14/2005	Leuven K U Res & Dev et al.

EXAMINER <i>/Niloofar Rahmani/</i>	DATE CONSIDERED 09/02/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	WO-06/029966	3/23/2006	Ciba Sc Holding Ag et al.
	WO-06/033703	3/30/2006	Gilead Sciences Inc et al.
	WO-06/069193	6/29/2006	Gilead Sciences Inc et al.
	WO-08/005519	1/10/2008	Gilead Sciences Inc et al.
	WO-09/009001	1/15/2009	Gilead Sciences Inc et al.
	WO-92/22556	12/23/1992	Cheil Foods & Chem
	WO-93/02080	2/4/1993	British Bio Technology
	WO-93/14072	7/22/1993	British Bio Technology
	WO-93/16075	8/19/1993	British Bio Technology
	WO-94/12461	6/9/1994	Pfizer et al.
	WO-94/29321	12/22/1994	Cheil Foods & Chem
	WO-95/02597	1/26/1995	Minnesota Mining & Mfg
	WO-95/16687	6/22/1995	Abbott Laboratories
	WO-96/11192	4/18/1996	Searle & Co. et al.
	WO-96/15111	5/23/1996	Univ Minnesota

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Akamatsu et al., "New Efficient Route for Solid-Phase Synthesis of Benzimidazole Derivatives," <i>J. Comb. Chem.</i> 4:475-483 (2002).
	Baba et al., "Synergistic Antiviral Effects of Antitherpes Compounds and Human Leukocyte Interferon on Varicella-Zoster Virus <i>In Vitro</i> ," <i>Antimicrobial Agents Chemother.</i> 25:515-517, 1984.
	Baginski et al., "Mechanism of Action of a Pestivirus Antiviral Compound," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 97:7981-7986, 2000.
	Barlin and Fenn, "A Carbon-13 Nuclear Magnetic Resonance Study of Protonation in Imidazo[4,5-c]pyridines," <i>Aust. J. Chem.</i> 34:1341-1344 (1981).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

EXAMINER	/Niloofar Rahmani/	DATE CONSIDERED	09/02/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Barlin and Fenn, "The Preparation and 1H NMR Spectra of Some N-Methylpurines and Related Compounds," <i>Aust. J. Chem.</i> 36:633-638 (1983).
	Barlin, "Ionisation Constants of Heterocyclic Substances, Part VIII. 1,3,5-Triazindenes," <i>J. Chem. Soc. B: Phys. Org.</i> 4:285-291, 1966.
	Barraclough et al., "An Adventitious Synthesis of a 5-Methylimidazo[4,5-c]pyridine Derivative," <i>Tet. Lett.</i> 27:5997-6000 (1986).
	Barraclough et al., "Inotropic "A" Ring Substituted Sulmazole and Isomazole Analogues," <i>J. Med. Chem.</i> 33:2231-2239 (1990).
	Brown et al., "Purine Analogues as Amplifiers of Phleomycin. V. Thioethers of Several Heterocyclic Systems with One or Two Rings," <i>Aust. J. Chem.</i> 32:2713-2726 (1979).
	Chou et al., "Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors," <i>Adv. Enzyme Reg.</i> 22:27-55, 1984.
	Cleve et al., "Derivate des Imidazo[4,5-b]- und Imidazo[4,5-c]-Pyridins," <i>Liebigs Ann. Chem.</i> 747:158-171, 1971 (and translation).
	Curtin et al., "Discovery and Evaluation of a Series of 3-Acyliindole Imidazopyridine Platelet-Activating Factor Antagonists," <i>J. Med. Chem.</i> 41:74-95 (1998).
	Elion et al., "Antagonists of Nucleic Acid Derivatives. VIII. Synergism in Combinations of Biochemically Related Antimetabolites," <i>J. Biol. Chem.</i> 208:477-488, 1954.
	Final Rejection, December 16, 2008, US 11/019,830
	Final Rejection, March 19, 2007, US 11/316,050
	Fletcher et al., "Heterocyclic Systems," <i>Nomenclature of Organic Adv. Ser.</i> pp. 49-64, 1974.
	Greenfield et al., "Increase in the Stability and Helical Content of Estrogen Receptor Alpha in the Presence of the Estrogen Response Element: Analysis by Circular Dichroism Spectroscopy," <i>Biochemistry</i> 40:6646-6652, 2001.
	Griesser, Chapter 8, The Importance of Solvates (pages 211-230), In the text, Polymorphism: In the Pharmaceutical Industry, Hilfiker, 2006
	Guillory (in Britain ed.) "Polymorphism etc." NY:marcel Dekker Inc. 1999, 1-2, 183-226
	International Preliminary Examination Report (PCT/BE03/00117) (mailed 3 September, 2004).
	International Preliminary Report on Patentability for PCT/US2004/043112 dated April 25, 2006.
	International Preliminary Report on Patentability for PCT/US2005/026606 dated February 20, 2007.
	International Preliminary Report on Patentability for PCT/US2005/046477 dated March 16, 2007.
	International Preliminary Report on Patentability for PCT/US2007/015553 dated January 13, 2009.
	International Search Report for PCT/BE2003/000117 dated December 16, 2003.
	International Search Report for PCT/US2005/026606 dated February 13, 2006.

EXAMINER	/Niloofar Rahmani/	DATE CONSIDERED	09/02/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50304/128001 10/583,814 Bondy et al. June 4, 2007 1625 June 11, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	International Search Report for PCT/US2005/046477 dated June 2, 2006.
	International Search Report for PCT/US2007/015553 dated March 6, 2008.
	International Search Report for PCT/US2008/008259 dated October 14, 2008.
	Jacob III, P., "Resolution of (+/-) 5-Bromonornicotine. Sythesis of (R)- and (S)- Nornicotine of High Enantiomeric Purity," <i>J. Org. Chem.</i> 47:4165-4167, 1982.
	Johnson, A.W. <i>Invitation to Organic Chemistry</i> 1999 Jones and Bartlett: Missisauga, Canada pg. 24
	Jones, Maitland <i>Organic Chemistry</i> Norton: New York, 1997, Pg. 84-99
	Kariv et al., "Improvement of 'Hit-to-Lead' Optimization by Integration of In Vitro HTS Experimental Models for Early Determination of Pharmacokinetic Properties," <i>Comb. Chem. High Throughput Screen.</i> 5:459-472, 2002.
	Kuno et al (1993) "Studies on Cerebral Protective Agents, IV. Synthesis of Novel 4-Arylpyridine and 4-arylpypyridazine Derivatives with Anti-Anoxic Activity," <i>Chem Phar. Bull.</i> 41(1):136-162
	Lindenbach et al. (2005) "Unraveling Hepatitis C Virus Replication from Genome to Function," <i>Nature</i> 436:-933-938
	Lochmüller et al., "Chromatographic Resolution of Enantiomers Selective Review," <i>J. Chromatography</i> 113:283-302, 1975.
	Mederski and Pachler, "Synthesis and Structural Assignment of Some N-Substituted Imidazopyridine Derivatives," <i>Tetrahedron</i> 48:10549-10558 (1992).
	Montgomery et al., "1-B-D-Arabinofuranosyl, etc.," <i>J. Med. Chem.</i> , 1982,25,96-98.
	Non-Final Rejection, December 12, 2008, US 10/519,756
	Non-Final Rejection, March 12, 2008, US 11/019,830
	Non-Final Rejection, March 25, 2009, US 12/022,557
	Non-Final Rejection, October 29, 2008, US 11/825,598
	Non-Final Rejection, September 27, 2006, US 11/316,050
	Okamoto et al., "Optical Resolution of Dihydropyridine Enantiomers by High-Performance Liquid Chromatography Using PhenylCarbamates of Polysaccharides as a Chiral Stationary Phase," <i>J. Chromatography</i> 513:375-378, 1990.
	Paeshuyse et al., "A Novel, Highly Selective, etc.," <i>J of Virology</i> , Jan. 2006, 80(1), 149-160.
	Puerstinger et al. "Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A new class of pestivirus inhibitors" <i>Bioorganic & Medicinal Chemistry Letters</i> 2006, 16:5345-5349
	Puerstinger et al. "Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: From anti-pestivirus to anti-hepatitis C virus activity" <i>Bioorganic & Medicinal Chemistry Letters</i> 2007, 17:391-393

EXAMINER	/Niloofar Rahmani/	DATE CONSIDERED	09/02/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/583,814
		Applicant Bondy et al.
		Filing Date June 4, 2007
		Group 1625
(37 C.F.R. § 1.98(b))		IDS Filed June 11, 2009

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Rigaudy et al., "Fundamental Heterocyclic Systems," <i>Nomenclature of Organic Adv. Ser.</i> pp. 53-76, 1979.
	Robertson et al., "Structure-Activity Relationships of Arylimidazopyridine Cardiotonics: Discovery and Inotropic Activity of 2-[2-Methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine," <i>J. Med. Chem.</i> 28:717-727 (1985).
	Savarino et al., "Spectral Behaviour of Linked Heterocyclic Systems and Related Dyes," <i>Spectrochim. Acta A: Mol. Biomol. Spectrosc.</i> 49A:1379-1393 (1993).
	Self et al. (1991) "Romzarit: A Potential Disease-Modifying Antirheumatic Drug," <i>J. Med. Chem.</i> 34:772-777
	Siddiqui et al., "3-Deaza- and, etc.," <i>J. Med. Chem.</i> , 1995, 38, 1035-1038.
	Stanovnik et al., "Methylation of Heterocyclic Compounds Containing NH, SH, and/or OH Groups by Means of N,N-Dimethylformamide Dimethyl Acetal," <i>Aust. J. Chem.</i> 34:1729-1738 (1981).
	Vassilev et al., "Authentic and Chimeric Full-Length Genomic cDNA Clones of Bovine Viral Diarrhea Virus That Yield Infectious Transcripts," <i>J. Virol.</i> 71:471-478 (1997).
	Vippagunta et al. "Crystalline Solid" <i>Advanced Drug Delivery Reviews</i> 48:3-26 (2001)
	Wang et al., "Non-Nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase. Crystal Structures and Mechanism of Inhibition," <i>J. Biol. Chem.</i> 278:9489-9495 (2003).
	Written Opinion for PCT/US2005/026606 dated February 13, 2006
	Written Opinion for PCT/US2005/046477 dated June 2, 2006
	Written Opinion for PCT/US2007/015553 dated January 7, 2009
	Zhang, "Inhibitors of Hepatitis C -- A Review of the Recent Patent Literature," <i>lDrugs</i> 5:154-158 (2002).
	Zhang, "Studies on the Synthesis and Single Crystal Structure of 3-methyl-6-(p-methylphenyl) Pyridazine," 2001 <i>Journal of Sichuan Normal University (Natural Science)</i> 24(4):384-386 (and translation)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

EXAMINER <i>/Niloofar Rahmani/</i>	DATE CONSIDERED <i>09/02/2009</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	